Sanofi-Aventis Renews Licenses for Genomatix Chip Analysis Pipeline
News Sep 28, 2007
Genomatix Software GmbH (Munich) announced today that Sanofi-Aventis has renewed its licenses for Multi-Site access to the Genomatix Microarray Analysis Pipeline.
The pipeline provides a fully integrated, user friendly solution for the analysis of expression and tiling microarray experiments, including the powerful ChIP on chip studies.
Genomatix software module ChipInspector seamlessly integrates with additional modules (BiblioSphere PathwayEdition, ElDorado, Gene2Promoter, and GEMS Launcher) to achieve a molecular level understanding of how genes are regulated and co-regulated, providing the scientists at Sanofi-Aventis a comprehensive gene network and pathway analysis.
Martin Seifert, Vice President Microarray Business and Collaborative Research at Genomatix stated: “We are pleased that our existing relationship with Sanofi-Aventis has led to an extension of their existing licensing agreement.
It confirms the validity of our integrated approach to understanding gene regulation by combining state of the art software, biological data bases, expert systems and scientific support, to provide a complete solution for the computational biologist.”
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE